Enable Accessibility
Enable Accessibility
Better Health,
Brighter Future
Newsroom
Careers
Contact Us
HCPs
English
français
Canada
Who We Are
About Takeda
How can we do more for our patients?
Everything at Takeda starts with this question.
Learn more
Company Information
Company Facts
History
Corporate Philosophy
About Takeda Canada
Message from the GM
Contact Us
Our Partnerships
Compliance
Takeda Worldwide
What We Do
Our Business
Takeda continues its transformation into an agile and innovative global pharmaceutical leader, serving the needs of patients and physicians worldwide.
Learn more
Research & Development
Conditions We Treat
ADHD
Crohn's Disease
Gastro esophageal reflux disease (GERD, heartburn)
Gaucher Disease
Hereditary Angioedema
Hunter Syndrome
Lung Cancer
Multiple Myeloma
Short Bowel Syndrome
Ulcerative Colitis
Our Medicines
Medications Return Program
Helping Canadian Patients
Our Pipeline of New Treatments
OnePath Patient Support Program
Vyvanse Assistance Program
How Takeda Canada does Business
Canadian R&D Initiatives
Our Stories
Our Stories
Find out Takeda's stories related on Innovation, Caring and Heritage
Learn more
Innovation
Caring
Heritage
Corporate Responsibility
Takeda's CSR
Takeda is committed to creating corporate value by developing outstanding pharmaceutical products and conducting corporate citizenship activities.
Learn more
Our Commitment
Giving Back to the Community
Product Donations
Grants, Donations and Sponsorships
COVID-19
HOME
Newsroom
News Releases
Share:
Newsroom
News Releases
News Releases
News Releases
Enter
Year of release
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
January, 2023
January 17, 2023
2023-01-17
Takeda Recognized as a Top Employer in Canada in 2023
December, 2022
December 1, 2022
2022-12-01
LIVTENCITY maribavir receives positive CADTH recommendation for adults with post-transplant cytomegalovirus CMV infection
November, 2022
November 21, 2022
2022-11-21
Takeda Receives Prestigious Prix Galien Canada Innovative Product Award for TAKHZYRO lanadelumab
November 8, 2022
2022-11-08
THE CANADIAN INFLAMMATORY BOWEL DISEASE RESEARCH CONSORTIUM AWARDS FIRST 1M PIONEER GRANT FROM TAKEDA CANADA
November 4, 2022
2022-11-04
Building a Successful Rare Disease Strategy is Our Shared Responsibility
October, 2022
October 17, 2022
2022-10-17
Takeda Releases Report on the Importance of Defining Rare Disease in Canada
September, 2022
September 20, 2022
2022-09-20
Health Canada approves Takeda’s LIVTENCITY™ (maribavir)
September 7, 2022
2022-09-07
Takeda Canada Partners with the CIHR to Advance Research in Rare Diseases
1
2
3
4
5
TOP
Close
